# 2025å¹´å…¬å…±å«ç”Ÿæµè¡Œç—…å­¦ç ”ç©¶è¿‘å†µ - å­¦ä¹ ç¬”è®°
# 2025 Public Health & Epidemiology Research - Learning Notes

## ğŸ“‹ å‰§é›†æ¦‚è§ˆ

| å­—æ®µ | ä¿¡æ¯ |
|------|------|
| **æ’­å®¢æ ‡é¢˜** | 2025å¹´å…¬å…±å«ç”Ÿæµè¡Œç—…å­¦ç ”ç©¶è¿‘å†µ |
| **å‰§é›†ç¼–å·** | 001 |
| **æ—¶é•¿** | 15åˆ†é’Ÿ |
| **éš¾åº¦** | ä¸­çº§ (Intermediate) |
| **ä¸»é¢˜** | æµè¡Œç—…å­¦é‡ç‚¹ç§‘å­¦å‘ç° |
| **ä¸»æ’­** | Matthew |
| **æ—¥æœŸ** | 2026-02-11 |
| **æ¥æº** | Scientific American, Knowable Magazine, JHU |

---

## ğŸ¯ å­¦ä¹ ç›®æ ‡

å®Œæˆæœ¬å‰§é›†å­¦ä¹ åï¼Œä½ å°†èƒ½å¤Ÿï¼š

- [ ] ç†è§£2025å¹´äº”å¤§å…¬å…±å«ç”Ÿå‘ç°
- [ ] æŒæ¡15ä¸ªæ ¸å¿ƒæµè¡Œç—…å­¦æœ¯è¯­ï¼ˆåŒ…å«ä¸­æ–‡æ„æ€ï¼‰
- [ ] ç”¨è‹±è¯­è§£é‡Šç–«è‹—ä¸ç¥ç»é€€è¡Œæ€§ç–¾ç—…çš„å…³ç³»
- [ ] è®¨è®ºGLP-1è¯ç‰©çš„ä½œç”¨æœºåˆ¶
- [ ] æè¿°One Healthç†å¿µ

---

## ğŸ“ å‰§é›†æ‘˜è¦

### ç®€è¦æ¦‚è¿° (3-5å¥è¯)

2025å¹´ï¼Œå°½ç®¡ç§‘å­¦ç ”ç©¶é¢ä¸´èµ„é‡‘å‰Šå‡ç­‰æŒ‘æˆ˜ï¼Œæµè¡Œç—…å­¦é¢†åŸŸä»å–å¾—äº†é‡å¤§çªç ´ã€‚ç ”ç©¶å‘ç°äº†å¸¦çŠ¶ç–±ç–¹ç–«è‹—å¯èƒ½é™ä½é˜¿å°”èŒ¨æµ·é»˜ç—…é£é™©ï¼Œè¯ºè´å°”å¥–è¡¨å½°äº†å…ç–«è°ƒèŠ‚ç»†èƒçš„å‘ç°ï¼ŒGLP-1è¯ç‰©æ­ç¤ºäº†æ”¹å˜é£Ÿç‰©åå¥½çš„æœºåˆ¶ï¼Œç¦½æµæ„Ÿç ”ç©¶å¼ºè°ƒäº†äººç•œå…±æ‚£ç—…é˜²æ§çš„é‡è¦æ€§ã€‚

### æ ¸å¿ƒè¦ç‚¹

1. **å¸¦çŠ¶ç–±ç–¹ç–«è‹—ç ”ç©¶**ï¼šå¨å°”æ–¯ç ”ç©¶æ˜¾ç¤ºç–«è‹—æ¥ç§è€…æ‚£ç—´å‘†ç—‡é£é™©é™ä½20%
2. **è¯ºè´å°”ç”Ÿç†å­¦æˆ–åŒ»å­¦å¥–**ï¼šè¡¨å½°è°ƒèŠ‚æ€§Tç»†èƒåœ¨å…ç–«è€å—ä¸­çš„å…³é”®ä½œç”¨
3. **GLP-1è¯ç‰©æ–°å‘ç°**ï¼šè§£é‡Šé£Ÿç‰©åå¥½å˜åŒ–å’Œé…’ç²¾æ‘„å…¥å‡å°‘çš„æœºåˆ¶
4. **ç¦½æµæ„Ÿè·¨ç‰©ç§ä¼ æ’­**ï¼šH5N1ç—…æ¯’åœ¨å®¶ç¦½ã€ç‰›ç¾¤å’Œé‡ç”ŸåŠ¨ç‰©ä¸­çš„ä¼ æ’­è·¯å¾„
5. **ç”·æ€§é¿å­•è¯çªç ´**ï¼šé¦–ä¸ªé€šè¿‡IæœŸå®‰å…¨è¯•éªŒçš„éæ¿€ç´ å£æœé¿å­•è¯

---

## ğŸ“– è¯æ±‡ç§¯ç´¯

### æ ¸å¿ƒè¯æ±‡ (15ä¸ª)

| # | è¯æ±‡ | éŸ³æ ‡ | è¯æ€§ | å®šä¹‰ | ä¸­æ–‡ | ä¾‹å¥ | é¢‘ç‡ |
|---|------|------|------|------|------|------|------|
| 1 | **Neurodegenerative** | /ËŒnjÊŠÉ™rÉ™ÊŠdÉªËˆdÊ’enÉ™rÉ™tÉªv/ | adj. | Relating to degeneration of nerve cells | ç¥ç»é€€è¡Œæ€§çš„ | "Alzheimer's is the most common neurodegenerative disease." | â˜…â˜…â˜…â˜…â˜† |
| 2 | **Immune tolerance** | /ÉªËˆmjuËn ËˆtÉ’lÉ™rÉ™ns/ | n. | Immune system not attacking the body | å…ç–«è€å— | "Regulatory T cells maintain immune tolerance." | â˜…â˜…â˜…â˜…â˜… |
| 3 | **Hypothesis** | /haÉªËˆpÉ’Î¸É™sÉªs/ | n. | Proposed explanation | å‡è®¾ | "The virus-dementia hypothesis was supported." | â˜…â˜…â˜…â˜…â˜† |
| 4 | **Pandemic** | /pÃ¦nËˆdemÉªk/ | n./adj. | Global disease outbreak | å¤§æµè¡Œç—… | "Pandemic preparedness requires international cooperation." | â˜…â˜…â˜…â˜…â˜… |
| 5 | **Microbiome** | /ËˆmaÉªkrÉ™ÊŠbaÉªÉ™m/ | n. | Community of microorganisms | å¾®ç”Ÿç‰©ç»„ | "The gut microbiome affects overall health." | â˜…â˜…â˜…â˜…â˜… |
| 6 | **Dementia** | /dÉªËˆmenÊƒÉ™/ | n. | Cognitive decline disease | ç—´å‘†ç—‡ | "Alzheimer's is the leading cause of dementia." | â˜…â˜…â˜…â˜…â˜† |
| 7 | **Regulatory T cells** | /ËˆreÉ¡jÉ™lÉ™tÉ”Ëri tiË selz/ | n. | Cells suppressing immune response | è°ƒèŠ‚æ€§Tç»†èƒ | "Regulatory T cells act as peacekeepers." | â˜…â˜…â˜…â˜†â˜† |
| 8 | **Contraceptive** | /ËŒkÉ’ntrÉ™ËˆseptÉªv/ | n./adj. | Birth control | é¿å­•è¯ | "A new male contraceptive passed safety trials." | â˜…â˜…â˜…â˜†â˜† |
| 9 | **Avian influenza** | /ËˆeÉªviÉ™n ËŒÉªnfluËˆenzÉ™/ | n. | Bird flu infection | ç¦½æµæ„Ÿ | "Avian influenza spread through dairy cattle." | â˜…â˜…â˜…â˜†â˜† |
| 10 | **Reversible** | /rÉªËˆvÉœËsÉ™bl/ | adj. | Can be undone | å¯é€†çš„ | "The contraceptive's effects are reversible." | â˜…â˜…â˜…â˜…â˜† |
| 11 | **One Health** | /wÊŒn helÎ¸/ | n. | Human-animal-environment health | åŒä¸€å¥åº· | "One Health approach connects human and animal health." | â˜…â˜…â˜…â˜†â˜† |
| 12 | **Gut-brain axis** | /É¡ÊŒt breÉªn ËˆÃ¦ksÉªs/ | n. | Gut-brain communication | è‚ è„‘è½´ | "GLP-1 drugs affect the gut-brain axis." | â˜…â˜…â˜…â˜†â˜† |
| 13 | **Butyrate** | /ËˆbjuËtÉªreÉªt/ | n. | Fatty acid for digestion | ä¸é…¸ç› | "Butyrate aids digestion and nutrient absorption." | â˜…â˜…â˜†â˜†â˜† |
| 14 | **Alcohol consumption** | /ËˆÃ¦lkÉ™hÉ’l kÉ™nËˆsÊŒmpÊƒn/ | n. | Alcohol intake | é¥®é…’é‡ | "GLP-1 drugs may reduce alcohol consumption." | â˜…â˜…â˜…â˜…â˜† |
| 15 | **Food preferences** | /fuËd ËˆprefrÉ™nsÉªz/ | n. | Food choices | é£Ÿç‰©åå¥½ | "The drug changed patients' food preferences." | â˜…â˜…â˜…â˜†â˜† |

### å­¦æœ¯å’Œä¸“ä¸šè¡¨è¾¾

| è¡¨è¾¾ | å«ä¹‰ | ä¸­æ–‡ | è¯­å¢ƒ/ç”¨æ³• | ä¾‹å¥ |
|------|------|------|----------|------|
| **Provide evidence for** | æä¾›è¯æ®æ”¯æŒ | æä¾›...çš„è¯æ® | å­¦æœ¯è®¨è®º | "The study provides evidence for the virus-dementia link." |
| **Lower the risk of** | é™ä½...é£é™© | é™ä½...é£é™© | æµè¡Œç—…å­¦ | "Vaccination lowers the risk of dementia." |
| **Pass clinical trials** | é€šè¿‡ä¸´åºŠè¯•éªŒ | é€šè¿‡ä¸´åºŠè¯•éªŒ | è¯ç‰©ç ”å‘ | "The drug passed Phase I safety trials." |
| **Jump between species** | è·¨ç‰©ç§ä¼ æ’­ | è·¨ç‰©ç§ä¼ æ’­ | äººç•œå…±æ‚£ç—… | "The virus can jump between species." |
| **Raise questions about** | å¼•å‘è´¨ç–‘ | æå‡ºå…³äº...çš„é—®é¢˜ | ç ”ç©¶è®¨è®º | "The data raises questions about long-term safety." |
| **Be associated with** | ä¸...ç›¸å…³è” | ä¸...æœ‰å…³è” | ç»Ÿè®¡å­¦è¡¨è¾¾ | "Coffee is associated with gut health." |

### æ­é… (Collocations)

| æ­é… | å«ä¹‰ | ä¸­æ–‡ | ä¾‹å¥ |
|------|------|------|------|
| **Develop dementia** | æ‚£ç—´å‘†ç—‡ | æ‚£ç—´å‘†ç—‡ | "People were less likely to develop dementia." |
| **Immune system** | å…ç–«ç³»ç»Ÿ | å…ç–«ç³»ç»Ÿ | "Regulatory T cells protect the immune system." |
| **Spread through** | ä¼ æ’­é€šè¿‡ | é€šè¿‡...ä¼ æ’­ | "The virus spread through dairy cattle." |
| **Maintain tolerance** | ç»´æŒè€å— | ç»´æŒè€å— | "These cells maintain immune tolerance." |
| **Reduce consumption** | å‡å°‘æ‘„å…¥ | å‡å°‘æ¶ˆè€— | "Drugs may reduce alcohol consumption." |

---

## âœï¸ è¯­æ³•ä¸å¥å‹

### å…³é”®å¥å‹

1. **A provides the strongest evidence yet that...**
   - **ç»“æ„**: ä¸»è¯­ + æä¾› + æœ€å¼ºè¯æ® + thatä»å¥
   - **ç”¨æ³•**: ç”¨äºå¼ºè°ƒæŸé¡¹ç ”ç©¶çš„çªç ´æ€§å‘ç°
   - **ä¸­æ–‡**: æŸç ”ç©¶æä¾›äº†è¿„ä»Šä¸ºæ­¢æœ€å¼ºçš„è¯æ®è¡¨æ˜...
   - **ä¾‹å¥**: "The Welsh study provides the strongest evidence yet that vaccines can protect against dementia."
   - **ä½ çš„ç»ƒä¹ **: _____________________________________

2. **...raise questions about...**
   - **ç»“æ„**: ä¸»è¯­ + å¼•å‘é—®é¢˜ + aboutåè¯
   - **ç”¨æ³•**: è¡¨ç¤ºæŸå‘ç°å¼•å‘äº†å¯¹æŸäº‹çš„è´¨ç–‘æˆ–æ‹…å¿§
   - **ä¸­æ–‡**: ...å¼•å‘äº†å¯¹...çš„è´¨ç–‘
   - **ä¾‹å¥**: "New data raises questions about long-term GLP-1 drug use."
   - **ä½ çš„ç»ƒä¹ **: _____________________________________

3. **...be associated with...**
   - **ç»“æ„**: ä¸»è¯­ + ä¸...ç›¸å…³è”
   - **ç”¨æ³•**: è¡¨ç¤ºç»Ÿè®¡å­¦ä¸Šçš„å…³è”æ€§ï¼ˆéå› æœå…³ç³»ï¼‰
   - **ä¸­æ–‡**: ...ä¸...ç›¸å…³è”
   - **ä¾‹å¥**: "Regular coffee consumption is associated with gut health benefits."
   - **ä½ çš„ç»ƒä¹ **: _____________________________________

4. **Scientists are exploring how to use X for Y**
   - **ç»“æ„**: ç§‘å­¦å®¶ä»¬æ­£åœ¨æ¢ç´¢å¦‚ä½•ç”¨Xæ¥æ²»ç–—Y
   - **ç”¨æ³•**: æè¿°ç ”ç©¶åº”ç”¨æ–¹å‘
   - **ä¸­æ–‡**: ç§‘å­¦å®¶æ­£åœ¨æ¢ç´¢ç”¨Xæ²»ç–—Yçš„æ–¹æ³•
   - **ä¾‹å¥**: "Scientists are exploring how to use regulatory T cells for treating autoimmune diseases."
   - **ä½ çš„ç»ƒä¹ **: _____________________________________

### è¿‡æ¸¡è¯ä¸çŸ­è¯­

| ç±»åˆ« | è¯æ±‡/çŸ­è¯­ | ä¸­æ–‡ | ç”¨æ³• | ä¾‹å¥ |
|------|----------|------|------|------|
| æ·»åŠ ä¿¡æ¯ | **Furthermore** | æ­¤å¤– | æ·»åŠ ç±»ä¼¼è§‚ç‚¹ | "Furthermore, the vaccine may protect against other conditions." |
| æ·»åŠ ä¿¡æ¯ | **In addition** | å¦å¤– | æ·»åŠ æ”¯æŒç‚¹ | "In addition, we studied Parkinson's disease." |
| å¯¹æ¯” | **However** | ç„¶è€Œ | æ˜¾ç¤ºå·®å¼‚ | "The drug is effective. However, many patients stop taking it." |
| å¯¹æ¯” | **On the other hand** | å¦ä¸€æ–¹é¢ | æå‡ºæ›¿ä»£è§‚ç‚¹ | "Coffee has benefits. On the other hand, excessive consumption has risks." |
| å› æœ | **Consequently** | å› æ­¤ | æ˜¾ç¤ºç»“æœ | "Many stopped treatment. Consequently, weight regain occurred." |
| å› æœ | **Therefore** | å› æ­¤ | å¾—å‡ºç»“è®º | "Therefore, we need One Health approaches." |
| ä¸¾ä¾‹ | **For instance** | ä¾‹å¦‚ | å¼•å…¥ä¾‹å­ | "Many diseases have viral components. For instance, some cancers are virus-related." |
| ä¸¾ä¾‹ | **Such as** | ä¾‹å¦‚ | åˆ—ä¸¾ä¾‹å­ | "Autoimmune diseases such as diabetes and arthritis." |

---

## ğŸ“ ç†è§£æ£€æŸ¥

### å¿«é€Ÿå›é¡¾é—®é¢˜

1. **What percentage reduction in dementia risk did the shingles vaccine provide?**
   - **ç­”æ¡ˆ**: 20 percent reduction over seven years.
   - **ä¸­æ–‡**: å¸¦çŠ¶ç–±ç–¹ç–«è‹—åœ¨ä¸ƒå¹´å†…å°†ç—´å‘†ç—‡é£é™©é™ä½äº†20%ã€‚

2. **What are regulatory T cells sometimes called?**
   - **ç­”æ¡ˆ**: "Peacekeepers" (because they prevent immune overreaction).
   - **ä¸­æ–‡**: è°ƒèŠ‚æ€§Tç»†èƒæœ‰æ—¶è¢«ç§°ä¸º"å’Œå¹³å«å£«"ï¼ˆå› ä¸ºå®ƒä»¬é˜²æ­¢å…ç–«ååº”è¿‡åº¦ï¼‰ã€‚

3. **What percentage of people stop GLP-1 drugs within two years?**
   - **ç­”æ¡ˆ**: The vast majority (specific percentage not stated in the source).
   - **ä¸­æ–‡**: ç»å¤§å¤šæ•°äººåœ¨ä¸¤å¹´å†…åœæ­¢ä½¿ç”¨GLP-1è¯ç‰©ï¼ˆå…·ä½“ç™¾åˆ†æ¯”æœªæåŠï¼‰ã€‚

4. **What approach connects human, animal, and environmental health?**
   - **ç­”æ¡ˆ**: One Health approach.
   - **ä¸­æ–‡**: åŒä¸€å¥åº·æ–¹æ³•ã€‚

5. **What beneficial compound does Lawsonibacter asaccharolyticus produce?**
   - **ç­”æ¡ˆ**: Butyrate.
   - **ä¸­æ–‡**: ä¸é…¸ç›ã€‚

### è®¨è®ºè¯é¢˜

1. **Vaccines and neurodegenerative diseases / ç–«è‹—ä¸ç¥ç»é€€è¡Œæ€§ç–¾ç—…**
   - "Do you think viral infections might contribute to neurodegenerative diseases? Why or why not?"
   - *ä¸­æ–‡*: ä½ è®¤ä¸ºç—…æ¯’æ„ŸæŸ“ä¼šå¯¼è‡´ç¥ç»é€€è¡Œæ€§ç–¾ç—…å—ï¼Ÿä¸ºä»€ä¹ˆï¼Ÿ
   - *æŒ‡å¯¼*: Consider evidence from the shingles vaccine study.

2. **GLP-1 drug adherence / GLP-1è¯ç‰©ä¾ä»æ€§**
   - "What are the implications of most people stopping GLP-1 treatment within two years?"
   - *ä¸­æ–‡*: å¤§å¤šæ•°äººåœ¨ä¸¤å¹´å†…åœæ­¢GLP-1æ²»ç–—æ„å‘³ç€ä»€ä¹ˆï¼Ÿ
   - *æŒ‡å¯¼*: Think about drug adherence, cost, and side effects.

3. **One Health approach / åŒä¸€å¥åº·æ–¹æ³•**
   - "How might the One Health approach help prevent future pandemics?"
   - *ä¸­æ–‡*: åŒä¸€å¥åº·æ–¹æ³•å¦‚ä½•å¸®åŠ©é¢„é˜²æœªæ¥çš„å¤§æµè¡Œç—…ï¼Ÿ
   - *æŒ‡å¯¼*: Consider connections between human and animal health.

---

## ğŸ“Š å­¦ä¹ è¿›åº¦

### è‡ªæˆ‘è¯„ä¼°

| æŠ€èƒ½ | å­¦ä¹ å‰ | å­¦ä¹ å(1å‘¨) | å­¦ä¹ å(1æœˆ) |
|------|--------|-------------|-------------|
| è¯æ±‡é‡ | â­â­â˜†â˜†â˜† | â­â­â­â˜†â˜† | â­â­â­â­â˜† |
| ç†è§£èƒ½åŠ› | â­â­â˜†â˜†â˜† | â­â­â­â˜†â˜† | â­â­â­â­â˜† |
| å£è¯­è¡¨è¾¾ | â­â­â˜†â˜†â˜† | â­â­â­â˜†â˜† | â­â­â­â­â˜† |
| å†™ä½œèƒ½åŠ› | â­â­â˜†â˜†â˜† | â­â­â­â˜†â˜† | â­â­â­â­â˜† |

---

## ğŸ“… å­¦ä¹ è®¡åˆ’

| å¤©æ•° | æ´»åŠ¨ | æ—¶é—´ | å®Œæˆ |
|------|------|------|------|
| ç¬¬1å¤© | å¬æ’­å®¢+è®°ç¬”è®° | 20åˆ†é’Ÿ | [ ] |
| ç¬¬2å¤© | å¤ä¹ è¯æ±‡ | 15åˆ†é’Ÿ | [ ] |
| ç¬¬3å¤© | è¯­æ³•ç»ƒä¹  | 20åˆ†é’Ÿ | [ ] |
| ç¬¬4å¤© | å£è¯­ç»ƒä¹  | 15åˆ†é’Ÿ | [ ] |
| ç¬¬5å¤© | å†™ä½œç»ƒä¹  | 20åˆ†é’Ÿ | [ ] |
| ç¬¬6å¤© | è®¨è®º | 30åˆ†é’Ÿ | [ ] |
| ç¬¬7å¤© | è‡ªæˆ‘è¯„ä¼° | 15åˆ†é’Ÿ | [ ] |

---

## ğŸ“š å‚è€ƒæ¥æº

1. Scientific American. (2025). 10 Transformational Health Discoveries of 2025. https://www.scientificamerican.com/article/10-transformational-health-discoveries-of-2025/

2. Knowable Magazine. (2025). 2025: The year in science. https://knowablemagazine.org/content/article/society/2025/top-science-stories-of-the-year-2025

3. Johns Hopkins Bloomberg School of Public Health. (2025). Public Health in 2025: Year in Review. https://publichealth.jhu.edu/2025/public-health-in-2025-year-in-review

---

*å­¦ä¹ ç¬”è®°ç”Ÿæˆæ—¶é—´: 2026-02-11*
*ä½¿ç”¨English Learning Podcast Generator Skill v2.0*
*åŒ…å«ä¸­æ–‡ç¿»è¯‘å’Œè¯æ±‡ä¸­æ–‡æ„æ€*
